Bristol-Myers Squibb (BMY) Tops Q3 EPS by 14c, Offers FY20 and FY21 Guidance

Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $1.63, $0.14 better than the analyst estimate of $1.49. Revenue for the quarter came in at $10.5 billion versus the consensus estimate of $10.33 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2020 EPS of $6.25-$6.35, versus the consensus of $6.27.

Bristol-Myers Squibb sees FY2021 EPS of $7.15-$7.45, versus the consensus of $7.39.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Morgan Stanley upgrades CDW on stronger AI-driven server demand